Introduction {#s1}
============

Diabetes is a growing epidemic affecting more than 346 million people worldwide ([@B1]--[@B3]). The metabolic abnormalities associated with diabetes lead to altered platelet, endothelial cell, and smooth muscle cell function ([@B4]--[@B7]). Together, these changes promote systemic atherosclerosis and lead to the traditional micro- and macrovascular complications commonly observed in diabetes.

Morbidity and mortality in the population with diabetes are largely due to complications of atherosclerosis. Furthermore, vascular disease in one arterial bed increases the risk for concomitant vascular disease in other arterial territories ([@B8],[@B9]). Vascular disease in the peripheral arteries presents a significant burden to health care expenditure and represents a major cause of myocardial infarction, stroke, and limb morbidity ([@B10]--[@B12]). In addition, both diabetes and disease in the peripheral vasculature are associated with increased long-term mortality ([@B13]--[@B16]). However, the peripheral neuropathy associated with diabetes masks symptoms of atherosclerosis, making the true prevalence of disease in the peripheral arteries difficult to ascertain without additional testing and presenting a challenge to early identification and prevention of disease progression ([@B12],[@B17]).

Given the known clustering of traditional cardiovascular risk factors and coronary heart disease with diabetes, this study sought to investigate the independent association between diabetes and the presence and severity of vascular disease in the peripheral arteries. While several studies have evaluated the association between diabetes and lower extremity peripheral artery disease (PAD), few studies have explored carotid artery stenosis (CAS) or abdominal aortic aneurysms (AAA) in populations with and without diabetes, and no study to date has evaluated the association between diabetes and all three major vascular disease subtypes in a large unselected population. In this study, we aim to evaluate the association between diabetes and the presence and severity of PAD, CAS, and AAA in more than 3 million subjects.

Research Design and Methods {#s2}
===========================

Study Population {#s3}
----------------

A total of 3,696,778 primarily self-referred people participated in the Life Line Screening (LLS; Independence, Ohio) vascular survey at more than 20,000 screening sites, representing all 50 states and broad geographical and socioeconomic characteristics, between 2003 and 2008. As noted previously, the prevalence of different cardiovascular risk factors in this population database is similar to that of the general U.S. population ([@B18]). Using U.S. census data linked by the subject's zip code, we categorized individuals based on income and education and found fairly good representation across different levels of socioeconomic status ([@B19]). A variety of costs was incurred by the individuals based on the package of tests purchased. All LLS sites use identical protocols and are subject to a quality control program ([@B18]). In accord with the Office for Human Research Protections, this study is exempt from review by an institutional review board ([@B20]).

Covariates {#s4}
----------

Participants completed a two-page questionnaire, providing their demographic information, height and weight, and medical and surgical history, including cardiovascular risk factors, physical activity, nutrition, and family history of cardiovascular disease. Obesity was identified as BMI ≥30 kg/m^2^, and tobacco use was defined as use of at least 100 cigarettes during their lifetime and currently smoking (current) or not currently smoking (former). Hypertension was defined as systolic blood pressure of ≥140 mmHg in either upper extremity or self-reported physician diagnosis or medication use. Hypercholesterolemia was defined as self-reported physician diagnosis or medication use. History of coronary artery disease was defined as having a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass graft. Diabetes was defined as self-reported physician diagnosis or medication use.

Vascular Disease Outcomes {#s5}
-------------------------

Presence of PAD was assessed with the bilateral ankle-brachial pressure index (ABI), defined as systolic blood pressure in the left and right ankle (measured in the posterior tibial artery or dorsalis pedis artery if a posterior tibial artery Doppler signal was inaudible) divided by the highest of the two systolic blood pressures in the left or right arm (brachial artery). In the overall population, 5.6% (*n* = 207,818) did not have recorded ABI results. PAD was defined as either left or right ABI ≤0.9 or history of peripheral arterial intervention. PAD was defined as symptomatic if participants had a prior revascularization procedure or answered yes to, "Do you have aching or pain in the legs that is worse with walking or running" or "...relieved within a few minutes by rest." Degree of PAD was categorized as normal (ABI 0.91--1.4), mild (ABI 0.81--0.90), moderate (ABI 0.61--0.80), severe (ABI ≤0.60), or unable to compress artery (ABI \>1.4) ([@B17]).

Presence of CAS was assessed using duplex ultrasound, and in the population of interest, 2.9% (*n* = 107,318) did not have carotid ultrasound results recorded. CAS was defined as CAS ≥50% or history of carotid artery revascularization procedure. Symptomatic CAS was defined as participants with a prior stroke, transient ischemic attack, or operation on the carotid arteries. The degree of CAS was categorized as moderate for 50--69% stenosis or severe for ≥70% stenosis.

All participants had abdominal aortic ultrasound results recorded, and AAA was defined as presence of an infrarenal abdominal aortic diameter of ≥3 cm on ultrasound (the greater of the anteroposterior or transverse measurement was used) or prior surgical or special procedure to repair an AAA. If a participant had a history of AAA repair, they were considered symptomatic.

Statistical Analysis {#s6}
--------------------

Each individual was assigned a unique identifier, and the investigators had access only to de-identified data. The population of interest was categorized into those with versus those without diabetes. Baseline characteristics and the presence of PAD, CAS, and AAA between participants with and without diabetes were compared using the χ^2^ test for proportions and a two-sided independent sample *t* test for continuous variables. Odds ratios (ORs) and 95% CIs were assessed using a logistic regression model to examine the strength of association between diabetes and PAD, CAS, and AAA. In addition to unadjusted OR, model 1 adjusted for age, sex, and race, whereas model 2 adjusted for age, sex, race, BMI, hypertension, hyperlipidemia, tobacco use, coronary artery disease, and stroke or transient ischemic attack. In sex-specific analysis, the strength of association between diabetes and PAD, CAS, and AAA was evaluated using the logistic regression model in model 2. The Wald test was used for testing interaction between the presence of diabetes and sex for the presence of each of the vascular disease subtypes. All statistical analyses were performed with PASW (version 18.0; SPSS Inc., Chicago, IL), SAS (version 9.12; SAS Institute Inc., Cary, NC), and the R package (R Development Core Team; available from <http://www.r-project.org/>).

Results {#s7}
=======

Baseline Characteristics {#s8}
------------------------

Among 3,696,778 participants in this analysis, 399,884 (10.8%) had diabetes. Baseline characteristics of participants with and without diabetes are shown in [Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-2432/-/DC1). Consistent with prior observations, participants with diabetes were older, more frequently male, less frequently white, and more likely to have other cardiovascular risk factors. These differences were consistent across the spectrum of vascular disease. Subjects with vascular disease had a higher prevalence of risk factors than subjects without vascular disease. Subjects with AAA were more likely to be men and had a higher prevalence of heart disease and stroke than subjects with PAD or CAS ([Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-2432/-/DC1)).

Prevalence of Vascular Disease {#s9}
------------------------------

Among the 3,696,778 participants in the study, 422,501 participants had any vascular disease; 233,958 participants had PAD, 193,734 participants had CAS, and 73,443 participants had AAA. Participants with diabetes had a higher prevalence of any vascular disease (unadjusted OR 1.98 \[95% CI 1.96--2.00\]; *P* \< 0.0001) ([Fig. 1](#F1){ref-type="fig"}). Diabetes was associated with a higher odds of PAD (unadjusted OR 1.96 \[95% CI 1.94--1.98\]; *P* \< 0.0001), CAS (unadjusted OR 2.13 \[95% CI 2.11--2.16\]; *P* \< 0.0001), and AAA (unadjusted OR 1.40 \[95% CI 1.37--1.43\]; *P* \< 0.0001) compared with those without diabetes ([Table 1](#T1){ref-type="table"}). Vascular disease in more than one peripheral vascular bed was also more common in participants with diabetes. Compared with participants without diabetes, participants with diabetes were more likely to have peripheral vascular disease in one territory (15.1% vs. 9.0%; *P* \< 0.0001), two territories (2.9% vs. 1.2%; *P* \< 0.0001), or three territories (0.7% vs. 0.4%; *P* \< 0.0001) ([Supplementary Fig. 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-2432/-/DC1)).
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After adjustment for age, sex, race, hypertension, hyperlipidemia, smoking status, BMI, coronary artery disease, and stroke or transient ischemic attack, diabetes was significantly associated with increased odds of any vascular disease (adjusted OR 1.41 \[95% CI 1.39--1.42\]; *P* \< 0.0001). A significant interaction existed between diabetes and vascular disease phenotype (*P* \< 0.0001); diabetes was significantly associated with increased odds of PAD (adjusted OR 1.42 \[95% CI 1.41--1.44\]; *P* \< 0.0001) and CAS (adjusted OR 1.45 \[95% CI 1.43--1.47\]; *P* \< 0.0001). In contrast, after multivariable adjustment, diabetes was significantly associated with lower odds of AAA (adjusted OR 0.86 \[95% CI 0.84--0.88\]; *P* \< 0.001) ([Table 1](#T1){ref-type="table"}).

Vascular Disease Severity {#s10}
-------------------------

The relationship between severity of vascular disease and diabetes across the spectrum of vascular phenotypes is shown in [Table 1](#T1){ref-type="table"} and [Fig. 2](#F2){ref-type="fig"}. Subjects with diabetes were more likely to have more severe PAD than subjects without diabetes. The association between diabetes and PAD became more pronounced with severity of disease (adjusted ORs: mild PAD, 1.37; moderate PAD, 1.77; severe PAD, 2.16; *P* for trend \< 0.001). Although less striking, a similar observation was noted in CAS; the association between diabetes and CAS increased with severity of disease (adjusted OR 1.53 \[95% CI 1.50--1.56\]; *P* \< 0.001 for moderate CAS and adjusted OR 1.60 \[95% CI 1.56--1.63\]; *P* \< 0.001 for severe CAS). For the end point of AAA, diabetes was associated with a 20% and 25% lower odds of smaller and larger AAA, respectively (adjusted OR 0.80 \[95% CI 0.77--0.83\]; *P* \< 0.001 for 3- to 5-cm-diameter aneurysm and adjusted OR 0.75 \[95% CI 0.66--0.85\]; *P* \< 0.001 for \>5-cm-diameter aneurysm).

![Proportion of survey participants with lower extremity PAD (*A*), CAS (*B*), and AAA (*C*) by disease severity in the population with and without diabetes (DM).](1636fig2){#F2}

[Supplementary Fig. 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-2432/-/DC1) shows the prevalence of vascular disease stratified by symptoms in participants with and without diabetes. Participants with diabetes were more likely to have both asymptomatic disease and symptomatic disease. To minimize recall bias in our analysis, we excluded subjects with symptomatic disease. Results were not greatly altered, with increased odds of PAD (adjusted OR 1.54 \[95% CI 1.50--1.57\]; *P* \< 0.0001) and CAS (adjusted OR 1.57 \[95% CI 1.55--1.60\]; *P* \< 0.0001) and decreased odds of AAA (adjusted OR 0.80 \[95% CI 0.77--0.83\]; *P* \< 0.0001).

Sex Differences {#s11}
---------------

We further investigated the association between diabetes and different phenotypes of vascular disease in women and men ([Table 2](#T2){ref-type="table"}). A significant association between diabetes and PAD and CAS was present in women and men, respectively. The association between diabetes and AAA seemed to differ by sex. Diabetes was associated with a 21% decreased odds of AAA in men, but no significant association between diabetes and AAA was noted among women (adjusted OR 0.99 \[95% CI 0.96--1.03\]; *P* = 0.76).
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Conclusions {#s12}
===========

In this large population-based analysis, all three major forms of vascular disease were significantly higher in people with diabetes compared with those without diabetes. However, after adjustment for baseline demographics and traditional risk factors, diabetes was significantly associated with an increased odds of PAD and CAS but lower odds of AAA. In support of this observation, the strength of association was more pronounced with increasing severity of disease in each of the three vascular phenotypes. Moreover, the positive association between diabetes and PAD and CAS, as well as the negative association between diabetes and AAA, remained robust in subjects with asymptomatic disease. Finally, the increased association between diabetes and PAD and CAS was similar in women and men; however, diabetes was associated with lower odds of AAA in men, which was not observed in women.

The results of this study are consistent with a recent analysis of more than 40,000 men without a history of cardiovascular disease at baseline who were followed for 25 years in the prospective Health Professionals Follow-up Study, which demonstrated an independent association between diabetes and PAD ([@B21]). Another study using National Health and Nutrition Examination Survey (NHANES) data demonstrated almost double the proportion of individuals with PAD in the population with diabetes compared with the overall population ([@B22]). In contrast to the current study, though, the ABI in the NHANES was measured using systolic blood pressure in only the right upper extremity, and the diagnosis of PAD did not include history of prior lower extremity revascularization ([@B22]). Furthermore, the authors noted an increase in the proportion of individuals with PAD in the elderly, non-Hispanic black, and Mexican American populations but did not perform adjusted analyses ([@B22]).

Our results demonstrating a significant positive association between diabetes and CAS are consistent with those reported in prior smaller cohorts. One study evaluating 1,058 patients referred for Doppler ultrasonography of the carotid arteries reported a significant association between diabetes and severe CAS (OR 2.77) in a multivariate logistic regression analysis that included age, sex, and ischemic heart disease ([@B23]). Another small prospective study evaluated 782 subjects (14% with diabetes) with high-resolution B-mode ultrasound and demonstrated a nonsignificant association between the presence of diabetes without cardiovascular disease and CAS (adjusted for age and sex: OR 2.16 \[95% CI 0.96--4.86\]; adjusted for age, sex, and cardiovascular risk factors: OR 2.19 \[95% CI 0.92--5.20\]) ([@B24]).

Unlike PAD and CAS, however, the odds of AAA in participants with diabetes significantly decrease after multivariate adjustment. Similar to our findings, a cross-sectional screening study of 73,451 veterans with no history of AAA demonstrated a negative association between the presence of diabetes and AAA in a multivariable model accounting for demographics and traditional cardiovascular risk factors (OR 0.68 \[95% CI 0.60--0.77\] for AAA 3.0--3.9 cm and OR 0.54 \[95% CI 0.44--0.65\] for AAA ≥4.0 cm, compared with \<3.0 cm) ([@B25]). Consistent with these results, a report of 6,142 veterans screened for AAA demonstrated that the presence of diabetes was associated with a normal aortic size ([@B26]). Another international, prospective, observational outpatient registry of 68,236 patients ≥45 years of age with established coronary, cerebral, or peripheral arterial disease or at least three vascular disease risk factors also demonstrated an inverse relationship between diabetes and AAA in a multivariate analysis (OR 0.59 \[95% CI 0.52--0.66\]) ([@B27]). Although these studies demonstrate a lower OR then that presented in the current study, the populations studied are different. For example, the studies from the Veterans Affairs System consisted almost entirely of men, and we found sex differences in the association between diabetes and AAA, whereas the international registry represents a highly selective population with established vascular disease or at high risk for vascular disease.

The significant interaction between diabetes and vascular phenotype requires important exploration. Although AAA is considered an atherosclerotic disease process (similar to PAD and CAS), an experimental mouse model demonstrated elevated glucose concentrations to be associated with increased plasminogen activator inhibitor-1 concentrations (concomitant with increased aneurysmal aortic *PAI-1* gene expression), reduced plasmin generation, and reduced abdominal aortic diameter, suggesting a role for the fibrinolytic pathway in AAA pathophysiology and a possible mechanism of inhibition of AAA disease in the presence of diabetes ([@B28]). A prospective cohort study of predominately men demonstrated the development of thicker aortic walls in diabetes, a reduction in the secretion of matrix metalloproteinase, and, thereby, reduced aortic wall stress and subsequent development of AAA ([@B29]). This is consistent with a recent report of 360 patients (96% men) with small AAA; the study demonstrated an inverse correlation between diabetes and aneurysm growth ([@B30]).

It is interesting that we note a neutral association between diabetes and AAA in women. The majority of studies investigating AAA have included mostly men. The current study is one of the few with a large number of women (\>2 million). One report of 9,342 women did demonstrate a six-times lower prevalence of AAA in women than men but did not comment on the prevalence of AAA by diabetes status ([@B31]). In addition, one meta-analysis of more than 15,000 patients from 18 studies, the majority of which consisted of more than 80% men, demonstrated that female sex was not associated with aneurysm growth; however, it did not comment on the association between female sex and the prevalence of AAA ([@B32]). The underlying mechanism for the sex disparities noted in the prevalence of AAA, and particularly in subjects with diabetes, needs further elucidation.

Limitations {#s13}
-----------

There are several limitations to this study, including those inherent to a retrospective observational study design. First, participants were provided access to the LLS measures for a fee; therefore the cohort may underrepresent people from lower socioeconomic backgrounds. Second, the diagnosis of diabetes was based on participant self-report and was not verified by medical records. Nonetheless, we found that the prevalence of diabetes was 10.8%, which is similar to the prevalence of diabetes noted in more representative populations (e.g., NHANES \[9.7%\] and 2013 American Heart Association heart disease and stroke statistics \[11.8%\]). Third, while ABI was measured during PAD screening in this survey, the toe brachial pressure index could be used to establish the diagnosis of PAD in people in whom PAD is clinically suspected, but ABI tests are unreliable because of noncompressible vessels, such as in people with long-standing diabetes or advanced age. However, this population comprises only 1.2% of the total cohort with available ABI data and is therefore unlikely to have a significant effect on the differences detected. In addition, in this study, ABI was measured using the posterior tibial artery; the dorsalis pedis artery was used only when the posterior tibial artery was inaudible. The highest of the dorsalis pedis or posterior tibial artery pressures at the ankle traditionally is used to form the calculation ([@B17]). However, a recent report compared this traditional method with an alternative method using the lower of the two ankle artery pressures, and both methods had similar diagnostic and predictive accuracy for all-cause and cardiovascular mortality, suggesting the utility of the alternate method in identifying a clinically meaningful population with PAD ([@B33]). Moreover, we expect any resulting misclassification to bias toward a null result. Fourth, severe PAD is defined in this study as ABI ≤0.6, whereas some definitions use ABI ≤0.4 to define severe PAD. We did evaluate the population with ABI \<0.4 and demonstrated similar results (adjusted OR 2.23 \[95% CI 2.07--2.41\]; *P* \< 0.001). Finally, while a small percentage (7.5%) of individuals did not have ABI calculated, did not receive carotid ultrasound screenings, or both, subjects excluded because of incomplete data were similar to the subjects included in the final analyses. Despite these limitations, this is the largest evaluation of the relationship between vascular disease in the peripheral arteries and diabetes, as well as the only study to examine all three major vascular subtypes in one cohort.

Conclusion {#s14}
----------

In a large contemporary survey, after adjustment of demographics and traditional risk factors, the presence of diabetes is associated with higher odds of PAD and CAS but lower odds of AAA. Future studies exploring this difference in vascular subtype and assessing the risks versus benefits of screening for PAD and CAS in asymptomatic people with diabetes are needed.

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc13-2432/-/DC1>.
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